Cystoid Macular Oedema in a Patient Treated with STING Agonist and Ezabenlimab for Disseminated Melanoma.

In the first-in-human trial with a STING agonist and ezabenlimab for melanoma, cystoid macular oedema emerged as a notable ocular side effect with vision worsening. This case highlights the importance of careful ocular monitoring in patients receiving this combination therapy. The cGAS-STING pathway is an important target for future research in treating ocular inflammatory conditions.